Technology
Health
Pharmaceutical
AcelRx Pharmaceuticals
$2.849876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$2.84
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.11 (3.94%) Today
-$0.06 (-2.07%) After Hours
Why Robinhood?
You can buy or sell ACRX and other stocks, options, ETFs, and crypto commission-free!
About
AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. Its products include sufentanil, DZUVEO, DSUVIA ZALVISO US and ZALVISO EU. Read More The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Redwood City, CA.
Employees
61
Headquarters
Redwood City, California
Founded
2005
Market Cap
228.68M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
2.14M
High Today
$2.93
Low Today
$2.76
Open Price
$2.79
Volume
945.46K
52 Week High
$5.05
52 Week Low
$1.99
Collections
Technology
Health
Pharmaceutical
US
North America
News
Yahoo FinanceMay 9
Edited Transcript of ACRX earnings conference call or presentation 8-May-19 8:30pm GMT
Q1 2019 AcelRx Pharmaceuticals Inc Earnings Call REDWOOD CITY May 9, 2019 (Thomson StreetEvents) -- Edited Transcript of AcelRx Pharmaceuticals Inc earnings conference call or presentation Wednesday, May 8, 2019 at 8:30:00pm GMT TEXT version of Transcript ================================================================================ Corporate Participants ================================================================================ * Pamela Pierce Palmer AcelRx Pharmaceuticals, Inc. - Co-Founder...
Yahoo FinanceMay 8
AcelRx Pharmaceuticals Reports Q1 Loss, Lags Revenue Estimates
AcelRx Pharmaceuticals (ACRX) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.23 per share a year ago.
PR NewswireMay 8
AcelRx Pharmaceuticals Reports First Quarter 2019 Financial Results
REDWOOD CITY, Calif., May 8, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its first quarter 2019 financial results. "I am very pleased with the progress made in the first five weeks of the DSUVIAâ„¢ launch. Shifting the paradigm in healthcare facilities to a new, non-invasive treatment option for acute pain will tak...
Price Paid on Robinhood
15% Lower
Right Now
52 Week Low
$1.99
Average Price Paid
$3.35
52 Week High
$5.05
Earnings
-$0.28
-$0.24
-$0.21
-$0.17
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.22 per share
Actual
-$0.17 per share